Depending on its expression levels, the long splice form of the pseudo-caspase FLIP (FLIP(L)) can act as an inhibitor (high expression) or activator (low expression) of apoptosis induction by the TRAIL-R2 death-inducing signalling complex (DISC); its expression levels are therefore tightly regulated. Here, we demonstrate that the Skp1-Cullin-1-F-box (SCF) Cullin-Ring E3 Ubiquitin Ligase complex containing Skp2 (SCF Skp2 ) regulates the stability of FLIP(L) (but not the short splice form FLIP(S)), and, unusually, this is mediated by direct binding of FLIP(L) to Cullin-1 rather than via Skp2. By fine mapping the interaction of FLIP(L) with Cullin-1 to the large subunit of its pseudo-caspase domain, we found that the interaction is significantly stronger with FLIP(L)'s DISC-processed p43-form.
Introduction
Programmed cell death (apoptosis) plays a key role in maintaining normal tissue homeostasis and preventing disease 1 . Apoptosis is orchestrated by a family of cysteine proteases, the caspases 2 . The multi-protein complexes formed following activation of the CD95 (Fas) and TRAIL-R1/R2 (DR4/DR5) death receptors by their ligands (FasL and TRAIL) expressed by immune effector cells and by 2 nd generation therapeutic agonists (ABBV621 and MEDI3039) is called the death-inducing signalling complex (DISC), consisting of the receptors, the adaptor molecule FADD, procaspase-8 and FLIP 3 .
Recruitment into these complexes exposes FADD's N-terminal death effector domain (DED), which recruits procaspase-8 by interacting with its N-terminal tandem DEDs 4 . Procaspase-8 homodimerization results in conformational changes in its catalytic domains that lead to its activation 5 . Two main splice forms of FLIP have been identified in humans: a long form (FLIP(L)) and a short form (FLIP(S)), both of which contain tandem DEDs and can be recruited to the DISC and related complexes (such as TNFR1 Complex II and the ripoptosome) where they form heterodimers with procaspase-8 4 . The relative amounts of FLIP(S) and FLIP(L) recruited to these complexes is a key determinant of cell fate (survival, apoptosis or necroptosis) and whether FLIP(L) acts as an inhibitor or activator of caspase-8-mediated apoptosis in these complexes depends on its stoichiometry relative to caspase-8; therefore FLIP(L) expression is tightly controlled at multiple levels 3, 4 .
and Supplementary Figure 2A-C) . We were subsequently able to fine map the Cullin-1/Skp2 interaction domain to a 13 amino acid region in FLIP(L) (Figure 3D-F) corresponding to amino acids 255-267 ( Figure 3G ). Skp2 normally binds to "phospho-degron" motifs on its substrates, which typically contain at least one phosphorylated Threonine or Serine 19 ; however, phosphorylation of Thr264 was not required for FLIP(L)'s interaction with Cullin-1/Skp2 (demonstrated by mutation of this residue to Alanine; Supplementary Figure 3A-D) . We also assessed whether Asp258, Glu263 or Glu265 were potentially acting as phospho-mimetic residues; however, mutation of these residues to alanine also failed to abrogate FLIP(L)'s interaction with Cullin-1/Skp2 (Supplementary Figure 3E ).
Nonetheless, we were able to show that the identified region of FLIP(L) was able to interact with all SCF Skp2 components, utilising a Biotin-tagged peptide incorporating the Cullin-1/Skp2 interaction region of FLIP(L) (plus additional flanking residues) ( Figure 3H) . Furthermore, using a model of the large and small catalytic subunits of the caspase-8/FLIP(L) heterodimer derived from its crystal structure 20 , we found that most of the 13 amino acid Cullin-1 interaction region (red) in the p20 subunit of FLIP(L) is present on the protein surface and therefore available for forming proteinprotein interactions (Figure 3I ). In addition, this region is adjacent to and interacts with FLIP(L)'s p12 subunit of its pseudo-catalytic domain (Supplementary Figure 4C) . FLIP(L) is cleaved between its large (p20) and small catalytic subunits by caspase-8 when it forms a heterodimer with caspase-8 at the DISC and related complexes; however, it is important to note that the small subunit remains associated with the heterodimer and is essential for its catalytic activity 20 .
FLIP(L) cleavage promotes its interaction with the SCF Skp2 complex.
Given the proximity of FLIP(L)'s SCF Skp2 interaction site to its p12-domain (Figure 3I and Supplementary Figure 4C) , we investigated the effect of FLIP(L)'s cleavage for its interaction with the SCF Skp2 complex. A C-terminal deletion corresponding to p43-FLIP (the caspase-8 cleavage product typically detected at the DISC) and a noncleavable form of FLIP(L) (NC-FLIP(L), D376A) were generated. Notably, p43-FLIP interacted more strongly with Cullin-1, Skp1 and Skp2 than the wild-type protein, whereas the NC-FLIP(L) interacted to the same extent (Figure 4A ). In addition, NC-FLIP(L) was significantly more stable than FLIP(L) and p43-FLIP ( Figure 4B) . These results suggest that cleavage of FLIP(L) to its p43-form promotes its interaction with the SCF Skp2 complex (potentially by relaxing the p20/p12 interface) and subsequent degradation via the UPS. As FLIP(L) cleavage to its p43-form is mediated by caspase-8 in a FADDdependent manner, we assessed whether these canonical DISC components could also interact with the SCF Skp2 complex. However, neither procaspase-8 nor FADD (nor as expected FLIP(S)) coimmunoprecipitated with Cullin-1 (Figure 4C) . This is consistent with the fact that the 13 amino acid Regulation of FLIP(L) and TRAIL signalling by SCF Skp2 JZ Roberts et al. 7 region in FLIP(L) that interacts with Cullin-1 is not conserved in procaspase-8, which has a 21 amino acid insertion in this region (Figure 3I and Supplementary Figure 4A-B) .
TRAF2 is another DISC-recruited protein that also plays a key role in death receptor signalling 21, 22 .
Moreover, TRAF2 has been reported to interact with FLIP(L) and (more strongly) p43-FLIP 23 , which we confirmed (Figure 4A) . Mapping studies re-confirmed the location of the Cullin-1:FLIP(L) interaction site and demonstrated that the TRAF2:FLIP(L) interaction site is located in an adjacent region, between amino acids 211 and 236 (Figure 4D and Supplementary Figure 4D ). TRAF2 coimmunoprecipitated with Cullin-1 in the presence of p43-FLIP or FLIP(L) and did not interact with caspase-8 or FADD (Figure 4C) , even though TRAF2 has been reported to act as an E3 ligase for caspase-8 at the DISC 24 . Moreover, in co-transfection experiments, the interaction of p43-FLIP with TRAF2, FADD and procaspase-8 was significantly reduced in cells co-transfected with Cullin-1 ( Figure   4E ), suggesting competition between these canonical DISC proteins and Cullin-1 for binding to p43-FLIP. In complementary co-transfection experiments, procaspase-8 disrupted the interaction of p43-FLIP with Cullin-1 ( Supplementary Figure 5A/B ). (Figure 3 ) indicate that FLIP(L) does not interact with the SCF Skp2 complex in a canonical manner; i.e. via a phosphodegron motif. We therefore assessed the requirement of Skp1 and Skp2 for FLIP(L)'s interaction with Cullin-1. In these experiments, we focussed on the more strongly interacting p43-FLIP. Notably, RNAi-mediated down-regulation of either Skp1 or Skp2 failed to abrogate the p43-FLIP:Cullin-1 interaction, although Skp1 silencing disrupted the interaction of Skp2 with p43-FLIP and Cullin-1 ( Figure 5A ), suggesting that Skp2's interaction with FLIP(L) is indirect and mediated by Cullin-1 via Skp1. Skp2 normally interacts with substrates via its leucine-rich repeat (LRR) domain and with Skp1 via its F-box domain; however, deletion of the LRR domain failed to disrupt p43-FLIP's interaction with Skp2, and the same was demonstrated with endogenous FLIP(L) (Figure 5B) , further suggesting that the interaction between FLIP(L) and Skp2 is indirect.
Mapping the FLIP(L) interaction site in the SCF Skp2 complex. The above results
We next generated two C-terminal deletions of Cullin-1 both lacking its C-terminal domain (CTD); one containing all 3 Cullin-Repeat (CR1-3) domains (CTD), and one containing only the N-terminal CR1 domain ( Figure 5C ). We found that the CR1 domain interacted with p43-FLIP ( Figure 5C-D) ; however, although this has been reported to be the Skp1-interacting domain 25 , we found that the CR1 domain did not interact with Skp1 (or Skp2) in isolation from CR2/3 (Figure 5D ), providing further evidence that FLIP(L) does not interact with Cullin-1 via Skp1/Skp2. Surprisingly, the interaction between p43-FLIP and the CR1-containing CTD truncation was significantly weaker than the CR1-only truncation (Figure 5C-D) ; the reason for this is unclear, but it may be that when the globular Cullin-1 CTD is deleted, non-physiological interactions between the three CR domains disrupt the ability of the CR1 domain to interact with p43-FLIP. It is also worth noting that the fraction of p43-FLIP associated with full-length Cullin-1 (and therefore Skp1, Skp2 and Rbx1) was extensively modified, potentially by polyubiquitin chains (Figure 5D ). Moreover, neither caspase-8 nor FADD were detected in this experiment, further confirming that these proteins do not interact with Cullin-1; however, an interaction with TRAF2 was detected in the presence of p43-FLIP.
Importantly, we were able to confirm a direct interaction between Cullin-1 and FLIP(L) by incubating recombinant Cullin-1 (rCul1) with the Biotin-tagged peptide corresponding to the mapped interaction site on FLIP(L) (amino acid residues 255-267; Figure 5E ). Collectively, the above results indicate that FLIP(L) directly interacts with the CR1 domain of Cullin-1 and that, unlike FADD and caspase-8, TRAF2 can potentially interact indirectly with Cullin-1 via FLIP(L) ( Figure 5F ).
NEDDylated Cullin-1 is associated with the TRAIL-R2 DISC.
Using a "DISC IP" assay for stimulating TRAIL-R2 DISC formation and then assessing the components of the complex 26 , we could detect Cullin-1, Rbx1, Skp1 and Skp2 associated with the TRAIL-R2 DISC in HCT116 p53 wild-type cells ( Figure 6A) . Notably, the levels of the SCF Skp2 complex recruited to the TRAIL-R2 DISC were higher in p53-deficient HCT116 cells, an effect not attributable to higher levels of expression of the complex's components ( Supplementary Figure 6A ), suggesting a role for p53 in complex formation. Very low, if any, SCF Skp2 complex components could be detected in the DISCs formed by LIM1215 and COLO205 cells ( Figure 6A ), although these models expressed low levels of the SCF Skp2 complex (Supplementary Figure 6A ) and cell surface TRAIL-R2 (as indicated by the amount of TRAIL-R2 immunoprecipitated).
The levels of interaction between SCF Skp2 and TRAIL-R2 DISC in the HT29 model were similar to those in the HCT116 models; however, although the RKO model expressed all the SCF Skp2 components to a similar level as HCT116 and HT29 cell lines (Supplementary Figure 6A) , very little SCF Skp2 was detected at the DISC despite significant cell surface TRAIL-R2 expression ( Figure 6A) . The levels of caspase-8 and FLIP at the DISC were also low at the RKO TRAIL-R2 DISC despite similar levels of expression (Supplementary Figure 6A ) and similar levels of FADD recruitment (Figure 6A ) to the other models. Of note, we also detected another CRL family member, Cullin-3, in these experiments; this is consistent with previous findings which reported that Cullin-3 promotes ubiquitin-dependent, DISC-mediated caspase-8 activation 27 . Importantly, despite similar expression of all SCF Skp2 components (Supplementary Figure 6B) , none of the components of the SCF Skp2 complex were detected in control experiments conducted in cells in which TRAIL-R2 had been deleted (Figure 6B) , confirming the specificity of the interaction. However, in cells lacking FADD, in which neither caspase-8 nor FLIP were recruited, Cullin-1 and the rest of the complex were detected at the DISC ( Figure 6B ), suggesting that the SCF Skp2 complex can interact with TRAIL-R2 in a FLIP-independent manner. This was further suggested by timecourse studies, in which components of the SCF Skp2 complex (and TRAF2) were all found to be associated with the unstimulated TRAIL-R2 (Figure 6C ; 0 min). Moreover, stimulation of TRAIL-R2 caused an initial loss of the receptor's association with SCF Skp2 , followed by re-association with similar dynamics as TRAF2 and canonical DISC proteins, FLIP, FADD and caspase-8.
Treating HCT116 cells with MLN4924 prior to DISC stimulation demonstrated that the form of Cullin-1 recruited to the DISC is its NEDDylated active form ( Figure 6D ). Furthermore, NEDDylated Cullin-1 was detected in membrane fractions, which were also enriched in TRAIL-R2 and canonical DISC and Proteasome inhibitors have previously been reported to enhance DISC-mediated caspase-8 activation by inhibiting TRAF2-mediated ubiquitination of its large catalytic subunit 24 . Given their roles in inhibiting UPS-mediated protein degradation at different points, we compared the impact of MLN4924 and MG132 on TRAIL-R2 DISC assembly ( Figure 6D ). Treatment with both MLN4924 and MG132 enhanced the levels of both p43-FLIP and TRAF2 detected at the TRAIL-R2 DISC (~1.7-fold and ~1.9-fold respectively when quantified relative to TRAIL-R2). MG132 but not MLN4924 also enhanced FLIP(S) levels at the DISC. Another notable effect of MLN4924 was to reduce the levels of poly-ubiquitinated caspase-8 detectable at the DISC; this is consistent with inhibition of Cullin-3- To determine the net effect of these MLN4924-induced changes in DISC composition on TRAILinduced apoptosis, we co-treated HCT116 cells with TRAIL and MLN4924 for 6h; enhanced levels of the active subunit of caspase-8 (p18) were detected by Western blot, and this correlated with enhanced PARP cleavage and caspase-8 activity (Figure 6E/F) ; similar results were also observed in cells pre-treated with MLN4924 (Supplementary Figure 7A) . In addition, the levels of p43-FLIP and p43/41-caspase-8 were elevated in MLN4924/TRAIL co-treated cells (Figure 6E) . Moreover, the effects of MLN4924 on caspase-8 and FLIP(L) processing were not due to downstream apoptosis signalling events as almost identical effects were observed in BAX-deficient cells (Figure 6E/F 
although full processing of caspase-3 leading to PARP cleavage in this model was inhibited (this was expected as HCT116 cells are "Type 2", meaning they require involvement of the mitochondrial apoptotic pathway to fully activate caspase-3 downstream of the DISC 34 ). These effects were maintained at longer timepoints (Supplementary Figure 7B) , and significantly enhanced TRAILinduced apoptosis in cells co-treated with MLN4924 was quantitatively confirmed (Figure 6G ).
Cullin-1 can regulate the composition and signalling outcomes of the TRAIL-R2 DISC. As MLN4924
affects multiple substrates, including Cullin-3, we assessed to what extent its effects on TRAIL-R2 composition and signalling are Cullin-1-dependent using a Cullin-1-directed siRNA pool (siCul1); the pan-caspase inhibitor (zVAD) was again used to allow us to visualise unprocessed FLIP(L) at the DISC and to inhibit apoptotic cell death induced by prolonged (48h) Cullin-1 silencing, which could have confounding effects on expression of DISC components. Increases in both forms of FLIP(L) and TRAF2 were observed in siCul1-transfected cells, along with a slight increase in FLIP(S) ( Figure 7A) . siCul1 had less impact on poly-ubiquitinated caspase-8 than MLN4924, consistent with this effect of the NEDDylation inhibitor being predominantly mediated via Cullin-3 24 , and its impact on RIPK1 levels was small. Collectively, these results indicate that the interaction of Cullin-1 with the TRAIL-R2 DISC decreases the levels of p43-FLIP and TRAF2 associated with the complex. The impact of these changes on TRAIL-induced apoptosis was similar to those observed for MLN4924, with increased levels of cleaved PARP and p18-caspase-8 ( Figure 7B ) and significantly enhanced cell death induction ( Figure 7C) . In HCT116 cells, siRNA-mediated down-regulation of FLIP(L) inhibited procasapse-8 processing at the TRAIL-R2 DISC thereby reducing the levels of fully processed p18-caspase-8 detected in the unbound fraction ( Figure 7D ). This indicates that FLIP(L) facilitates procaspase-8 processing in this setting and is consistent with the impact of MLN4924 treatment and Cullin-1
Discussion
FLIP is a major apoptosis-regulatory protein frequently overexpressed in solid and hematological cancers and is an important mediator of chemo-and radio-resistance as well as apoptosis induced by immune effector cells and therapeutic agonists [35] [36] [37] [38] . For these reasons, high FLIP expression has been correlated with poor prognosis in a number of cancers. FLIP is also critical for the survival of Tregs and MDSCs 39, 40 , key immunosuppressive cells in the tumor microenvironment. Moreover, through its roles (amongst others) in regulating activation-induced cell death (AICD) during the resolution of acute inflammatory responses, direct regulation of the NLRP3 and AIM2 inflammasomes 41 and survival of cardiomyocytes 42, 43 , FLIP has been linked to a number of other diseases and pathologies;
therefore, its precise regulation is vital for normal homeostasis.
The turnover of both FLIP splice forms is regulated by the UPS, with half-lives of ~45 minutes for FLIP(S) and ~3 hours for FLIP(L), which is indicative of distinct regulatory mechanisms for each splice form 6 . Although FLIP(S) lacks the pseudo-caspase C-terminal domain of FLIP(L), both proteins share the K192 and K195 residues that were identified as key ubiquitination sites 6 . A cytoplasmic complex termed the "FADDosome" formed in response to the antimetabolite 5-Fluorouracil was recently described containing FLIP, p53, ATR, caspase-10 and TRAF2, in which TRAF2 ubiquitinates FLIP(L) causing its degradation and activation of caspase-8-dependent apoptosis 44 . ER stress leading to JNKmediated activation of ITCH was reported to lead to ubiquitination and degradation of FLIP(L) 9, 10 .
Furthermore, recent studies suggest that the deubiquitinase (DUB) USP8 may interact with ITCH to regulate the relative expression of both splice forms. In this paper, we provide the first evidence for specific control of the long FLIP splice form by the SCF Skp2 Cullin-RING E3 Ligase complex.
The Cullin RING Ligase (CRL) family of E3 ligases account for roughly 20% of all proteasomal degradation within the cell 45, 46 , and many CRL proteins, especially the F-box family of proteins, have been linked to tumourgenesis 47 . NEDDylation is required for CRLs to be active. Using the NEDDylation inhibitor MLN4924 (pevonedistat), we found that FLIP(L) was a potential CRL substrate.
While FLIP downregulation in response to MLN4924 has been reported, this effect was observed using higher concentrations of MLN4924 over longer periods than used in our study 48, 49 ; and indeed we also observed a downregulation of FLIP(L) after 24hrs of treatment (Supplementary Figure 7B) .
Therefore, MLN4924 has a biphasic effect on FLIP(L), with early upregulation followed by downregulation potentially due to suppression of NFB, a known regulator of FLIP expression 50 and a known target of MLN4924 49, 51, 52 . In this study, we focussed on the more direct early effects of MLN4924 on FLIP(L) and the TRAIL-R2 DISC.
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Skp2 is an F-box protein linked to TRAIL-induced apoptosis 18 . This led us to us to investigate the most well characterised CRL, the SCF Skp2 complex. A specific interaction between SCF Skp2 and FLIP(L) but not FLIP(S) was detected in co-IP experiments. Downregulation of SCF Skp2 components with siRNA decreased FLIP(L) ubiquitination, while co-overexpression of Cullin-1 and Skp2 increased FLIP(L) ubiquitination in a NEDDylation-dependent manner. Furthermore, MLN4924 treatment stabilised FLIP(L) but not FLIP(S), leading us to the conclusion that SCF Skp2 could act as a selective E3 ligase for FLIP(L) and mediate its degradation via the UPS. Mapping experiments revealed that SCF Skp2 interacted with amino acids 255-267 within the p20 pseudo-catalytic domain of FLIP(L), a region which is not present in FLIP(S), nor its structurally-related paralogs caspase-8 and -10. Importantly, a stronger interaction with SCF Skp2 was detected with the p43-FLIP form of FLIP(L), which is usually generated by caspase-8 in FADD-dependent complexes such as the DISC. Molecular modelling studies using the crystal structure of the FLIP(L):procaspase-8 heterodimer indicated that the Cullin-1 binding site in FLIP(L)'s p20-subunit is partly buried in the interface with its p12-subunit, suggesting that cleavage between these domains by caspase-8 at the DISC may enhance the surface exposure of the Cullin-1-binding domain.
Notably, we found that SCF Skp2 could interact with TRAIL-R2 in a manner not dependent on FLIP or other canonical DISC components, FADD and caspase-8. Moreover, this interaction appears to be with the TRAIL-R2 pre-ligand association complex (PLAC) as it does not require receptor activation.
Thus, our data suggest a model in which processing of FLIP(L) to p43-FLIP at the TRAIL-R2 DISC enhances its interaction with co-localised SCF Skp2 , leading to targeting of p43-FLIP to the proteasome and reduced levels of the FLIP(L):caspase-8 heterodimer (Figure 7E) . This is consistent with the observed longer half-life of non-cleavable FLIP(L) and our observation that overexpressed Cullin-1 was able to disrupt p43-FLIP's interactions with FADD and caspase-8, indicative of competition between the SCF Skp2 complex and canonical DISC proteins for p43-FLIP binding. In this model in the absence of Cullin-1 (Figure 7F) , enhanced levels of the FLIP(L):caspase-8 heterodimeric enzyme at the TRAIL-R2 DISC would promote processing of its local substrates, including proximal procaspase-8 homodimers, thereby facilitating full processing of procaspase-8 to its pro-apoptotic p10/p18-form.
Canonically, SCF complexes interact with their substrates through their F-box protein; however, we found that p43-FLIP interacts directly with the CR1 domain of Cullin-1, independently of Skp1 and Skp2. Thus, FLIP(L)'s interaction with SCF Skp2 is more similar to other proteins known to regulate CRLs, such as CAND1 and subunits of the CSN complex (COP9 signalosome). SCF complexes are capable of auto-ubiquitination (a characteristic shared by many E3 ligases) and can degrade Skp2 in this manner 53 ; this is thought to be a negative feedback mechanism that stops these E3 ligases becoming overactive. Similarly, the direct interaction of FLIP(L) with Cullin-1 may trigger its ubiquitination. Direct binding of FLIP(L) to Cullin-1 may also disrupt Cullin-1's interactions with other substrates and may explain why FLIP(L) overexpression has been observed to inhibit β-catenin proteasomal degradation, which is induced by the Cullin-1-containing SCF β-TrCP complex 54, 55 .
Of note, Cullin-1 was predominantly detected in its NEDDylated (active) form at the TRAIL-R2 DISC, where we also detected the previously reported Cullin-3 27 . Inhibition of NEDDylated Cullin-1 using MLN4924 or downregulation of total Cullin-1 with siRNA was found to increase p43-FLIP levels at the DISC. By forming an enzymatically active heterodimer with p43/41-caspase-8 at the DISC, p43-FLIP can inhibit apoptosis when present at high levels or promote apoptosis when present at low levels.
In HCT116 cells, we found that siRNA-mediated downregulation of FLIP(L) inhibited procaspase-8 processing at the TRAIL-R2 DISC indicative of a pro-apoptotic role for FLIP(L) at the level of DISC stimulation used in these studies. Consistent with this, downregulation of NEDDylated-and total Cullin-1 using MLN4924 and siRNA respectively enhanced TRAIL-induced apoptosis in these cells, suggesting that by stabilizing p43-FLIP at the DISC, loss of Cullin-1 promotes p43-FLIP-mediated processing of procaspase-8 at the DISC and apoptosis induction. Moreover, the FLIP(L):caspase-8 heterodimer inhibits necroptosis by cleaving RIPK1, and we found reduced levels of RIPK1 at the DISC in the presence of MLN4924 (although not siCul1), suggestive of enhanced cleavage. FLIP(L)'s TRAF2 binding site, which we mapped to the linker region between DED2 and its p20 pseudo-caspase subunit, is adjacent to the Cullin-1 binding site, and although both can bind simultaneously (Figure 4D) , the binding of TRAF2 is clearly weakened by Cullin-1 (Figure 4E ), suggesting competition between the 2 proteins for binding to DISC-processed FLIP(L). Thus, in cells treated with MLN4924 or in which Cullin-1 was silenced, DISC recruitment of TRAF2 was enhanced along with FLIP(L). Our findings (Figures 6B/C) agree with those of others 56,57 that TRAF2 forms part of a FADD-and caspase-8-independent TRAIL-R2 PLAC and suggest that like other E3 ligases, c-Cbl/Cbl-b and A20, SCF Skp2 can also associate with the TRAIL-R2 PLAC. Moreover, our findings agree with earlier studies which reported that TRAF2 interacts with p43-FLIP at the DISC, leading to the latter's stabilisation 58 .
In conclusion, we have identified SCF Skp2 as a key regulator of FLIP(L) ubiquitination and stability.
Moreover, FLIP(L) can interact directly with Cullin-1; hitherto, the only direct Cullin-1-interacting proteins identified were Skp1, Rbx1, CAND1 and CSN2 and CSN4 of the COP9 Signalosome.
Moreover, we have found that SCF Skp2 can interact with both the TRAIL-R2 PLAC and DISC. Whereas heterodimers or caspase-8 homodimers) enhances its interaction with Cullin-1, which disrupts its interaction with caspase-8 and promotes its ubiquitination and proteasomal degradation by SCF Skp2 . This is facilitated by the constitutive interaction of SCF Skp2 with TRAIL-R2 and reduces the levels of the FLIP(L):caspase-8 heterodimeric enzyme at the DISC. (F) In the absence of Cullin-1, the FLIP(L):caspase-8 heterodimer promotes inter-dimer cleavage (1) between the small and large catalytic domains of proximal dimers. In the case of procaspase-8:procaspase-8 homodimers, this is followed by rapid intra-dimer cleavage (2) resulting in full processing of procaspase-8 to the proapoptotic p10/p12 hetero-tetramer. Oligonucleotide Transfections. A 3:1 ratio of FuGENE® HD Transfection Reagent (Promega) (µL) to plasmid DNA (µg) was used for transfections. In 100µL of OptiMEM (Life Technologies), FuGENE then plasmid DNA was added and left to incubate for 15 mins at room temperature. The mixture was then added to cells in culture and was left for 24-48h. For siRNA transfections, siRNA and Lipofectamine® RNAiMAX (Invitrogen) were added separately to OptiMEM (Life Technologies) before being mixed together and left to incubate at room temperature for 15 mins. Culture medium was then added to the mixture, to allow total cell coverage, and was used to replace the medium on cells, which was then left to incubate at 5% CO2, 37°C for 4h. Further culture medium was then added, to normal culturing levels, and then cells were left for 16-72h.
Supplementary Figure Legends
Immunoblotting. Cell lysates were prepared or immunoprecipitation (IP) samples were eluted using Loading buffer, subsequently followed by heating at 95°C for 5 mins. SDS-PAGE was then implemented to separate proteins by molecular weight and were then transferred to a nitrocellulose membrane. Protein expression was analysed by immunoblotting and detected using the G:BOX Chemi XX6 gel doc system (Syngene).
Ubiquitination Assay. Cells grown in a P90 plate, typically collected at over 80% confluency, were washed once in ice-cold PBS to stop dynamic ubiquitination events from occurring; all procedures were then conducted at 4°C for the same reason. Cells were transferred to tubes and were pelleted by centrifugation at 2400 rpm for 5 mins; supernatant was subsequently removed. Cells were then lysed with 250µL of SDS-free RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 5mM EDTA, 1% Triton X-100, dH 2 O), supplemented with an EDTA free protease inhibitor cocktail, for 20 mins before centrifugation at 13,00 rpm for 5 mins, followed by the supernatant being transferred to fresh tubes. 25µL of 10% SDS was added (Final concentration 1%) and the sample was heated at 95°C for 5 mins; to facilitate denaturation of the samples. The samples were then diluted with 750µL of SDS-free RIPA buffer, supplemented with an EDTA free protease inhibitor cocktail, to dilute the SDS and allow the immunoprecipitation (IP) antibody to function efficiently; samples were then incubated with 1µL of either FLIP (H-202) antibody (Santa Cruz biotechnology) or FLAG (M2) antibody (Sigma) overnight at 4°C while rotating. 30µL of the appropriate washed Dynabeads™ M-280 (Invitrogen) were then added to the samples and left to incubate for 6h at 4°C while rotating. The beads were then washed 5 times in SDS-free RIPA buffer and eluted in Loading buffer before being heated at 95°C for 5 mins.
Co-Immunoprecipitation (Co-IP).
Cells grown in a P90 plate, typically collected at over 80% confluency, were washed once in ice-cold PBS to stop disruption of protein:protein interactions; all procedures were then conducted at 4°C for the same reason. 1mL of SDS-free RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 5mM EDTA, 1% Triton X-100, dH 2 O), supplemented with an EDTA free protease inhibitor cocktail, was added onto cells within the plate and was left shaking for 20 mins. Cell lysates was then transferred to a tube, centrifuged at 13,000 rpm for 5 mins and the supernatant was transferred to a fresh tube. Either 1µL of FLIP (H-202) antibody (Santa Cruz biotechnology)/Myc-Tag (9B11) antibody (Cell Signaling Technology) or 20µL of FLAG (M2) Magnetic Beads (Sigma) were added to the cell lysates and were left to rotate overnight at 4°C. The following day 15µL of the appropriate washed Dynabeads™ M-280 (Invitrogen) were added to the samples and were left to rotate for a further 6h. The beads were then washed 5 times with SDS-Free RIPA buffer and were eluted in Loading buffer, followed by heating at 95°C for 5 mins. However, if the FLAG (M2) Magnetic Beads were used the Dynabeads step was skipped and beads were washed straight away.
TRAIL-R2 DISC IP. 1.2mg of anti-TRAIL-R2/DR5 antibody (Conatumumab, AMG655) (Amgen Inc.) was covalently attached to 60mg of Dynabeads in a volume of 6mL using the Dynabead® Antibody Coupling Kit (Life Technologies), according to the manufactory's instructions. Typically, a P90 plate containing 10mL of growth medium was inoculated with 30µL of anti-DR5 beads when cells were approximately 60% confluent. The cells were then washed once in ice-cold PBS to slow down DISC dynamics and further procedures were carried out at 4°C for the same reason. 1mL of DISC IP buffer (20mM Tris 7.4, 150mM NaCl, 0.2% NP-40, 10% Glycerol, dH 2 O), supplemented with an EDTA free protease inhibitor cocktail, was added onto cells within the plate and allowed to shake for 30 mins, then was transferred to a fresh tube. Anti-DR5 beads were isolated magnetically and washed 5 times with DISC IP buffer; the first flow-through was collected and termed the 'Unbound Fraction'. Beads were then eluted using Loading buffer and analysed by Immunoblotting. AMG655 is an agonist antibody for TRAIL-R2DR5, therefore, activating the receptor, when it is immunoprecipitated after being added to live cells any complexes that associate with active DR5 (like the DISC) are also immunoprecipitated as well.
Biotin Pulldown. For each sample, 25µL of Dynabeads™ MyOne™ Streptavidin T1 (Invitrogen) were first washed in SDS-free RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 5mM EDTA, 1% Triton X-100, dH 2 O) and then resuspended in SDS-Free RIPA+2% BSA for blocking. 20µg of the Biotin tagged peptide (peptides&elephants) was then conjuagted to the beads at room temperature of 30 mins while rotating. The conjugated beads were then washed with SDS-Free RIPA buffer and incubated with either rCullin-1 (abcam) or 50µg of cell lysate, collected in SDS-Free RIPA buffer supplemented with an EDTA free protease inhibitor cocktail, for 4h at 4°C while rotating. Beads were then washed with SDS-Free RIPA buffer and eluted in Loading buffer, followed by heating at 95°C for 5 mins.
PCR.
A PCR reaction mixture of 3µL of cDNA, 1µL DNase/RNase free water, 0.5µL Forward primer (5µM), 0.5µL Reverse primer (5µM) and 5µL LightCycler® 480 SYBR Green I Master reagent (Roche Diagnostics) was performed and analysed on a Roche LightCycler® 480 System (Roche Diagnostics). Relative mRNA levels were then normalised to the housekeeping gene (RPL24) and determined by the ΔΔCt method.
Site Directed Mutagenesis.
Site directed mutagenesis was carried out using the KOD Xtreme™ Hot Start DNA Polymerase kit (Merck). Briefly, a PCR reaction (100µL scale) incorporating 50µL 2x buffer, 20µL of 2mM dNTPs, 6µL each of 5µM forward and reverse primers (containing the desired mutations), 16µL of 10ng/µL template DNA and 2µL KOD polymerase was set up. 50µL of the completed PCR reaction mixture was then digested with 2.5µL Dpn1 and 5.8µL CutSmart® Buffer (New England Biolabs) for 3h at 37°C to degrade methylated template DNA. CaCL 2 competent DH5α bacteria when then transformed with the PCR mixture and subsequent colonies were picked and verified by DNA sequencing (GATC BIOTECH).
Caspase Activity Assay. 25µL of Caspase-Glo®-3/7 or -8 reagent (Promega) was added to 5µg (Caspase-3/7 activity) or 10µg (Caspase-8 activity) of cell lysate, made up to 25µL with PBS in a white-walled 96 well plate in duplicate. The plate was incubated in the dark at room temperature for 45 minutes and subsequently read at 1 sec integrated reads in a luminescent plate reader (Biotek Synergy 4 plate reader).
High Content Fluorescent Screening. Cells were seeded into a 96-well glass-bottomed plate (Cellvis) and left to adhere. After treatments, cells were incubated with 10x Annexin V Binding Buffer (BD Pharmingen), 1:1000 FITC Annexin V (BD Pharmingen), 0.333µg/mL Propidium Iodine (Sigma Aldrich) and 1.33µg/mL Hoechst 33342 (Thermo Fisher Scientific) for 20 mins at room temperature. The plate was then analysed on the ArrayScan™ XTI HCA Reader, integrated with the CrEST™ X-Light™ Confocal Scan Head (Thermo Fisher Scientific), and the HCS Studio Cell Analysis Software V6.6.0 (Thermo Fisher Scientific) was used to calculate the percentage of cells stained with Annexin V and Propidium Iodine. A target of 2000 cells was read in each well and all conditions were performed in triplicate.
Sub-Cellular Fractionation. The ProteoExtract® Subcellular Proteome Extraction Kit (Calbiochem) was used to generate lysates from the cytosolic, nuclear and cytoskeletal/lipid raft fractions of the cell, according to the manufacturer's instructions. The fractions were then subsequently analysed by immunoblotting.
Protein Half-life. Protein expression was analysed by Immunoblotting and quantified by densitometry, using ImageJ (NIH); normalising to the loading control. Treatment values were converted into ratios of its 0h timepoint (given the value 1) and were plotted. GraphPad Prism 5 was then used to generate a decay curve for treatments, by using the one phase exponential decay equation.
Statistical Analysis. Statistical significance was calculated from distinct technical replicates (n=3) by Two-way ANOVA with a Bonferroni post hoc test performed in GraphPad Prism 5. Graphs were plotted as means with error bars represented as SEM; statistical significance was denoted as follows: *** = p < 0.001, ** = p < 0.01, * = p < 0.05, ns = p>0.05. Procasp-8 FADD 55 28 Caspase-8 and FADD not detected 
